BACK(BACK)
BACK
10/8/26
IMAC (BACK)
Thursday
6:54 AM
ThesisOperational challenges and increased competition are leading to concerns about future profitability and market share.
Revenue Outlook
What Moves the Stock
- 01Changes in reimbursement rates from Medicare and private insurers
- 02Patient volume trends in outpatient orthopedic services
- 03Regulatory changes impacting healthcare delivery
- 04Expansion of facility locations in key markets
- 05Outpatient orthopedic services - 70%
- 06Rehabilitation therapies - 20%
- 07Other ancillary services - 10%
- 08Shift towards non-invasive orthopedic treatments
FY2024 Snapshot
- Revenue
- $72.0K
- Rev. Growth
- -98.6%
- Gross Margin
- -324%
- Op. Margin
- -7805%
- Net Margin
- -12555%
- Net Income
- $-9M
- NI Growth
- +4.0%
- EPS
- $-7.76
- 1Y Return
- -99.1%
BACK Chart
My Notes
- "Management indicated, 'We are facing headwinds that could impact our growth trajectory in the near term.'"
- Moat: IMAC's focus on non-surgical treatments provides a niche advantage, but it faces significant competition from larger players with more…
- growth - Investors looking for exposure to the outpatient healthcare sector and non-surgical treatment trends.
- Interest rates impact the cost of capital for facility expansion and renovations…
- Watch on earnings: Medicare reimbursement rate changes, Patient volume growth rate, Operating cash flow trends.
One Sentence Summary:
IMAC: the story is balanced — changes in reimbursement rates from medicare and private insurers.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers
